Although the initial choice to evaluate a 3-hour infusion of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was arbitrary, the attenuated schedule has since proven safe and active against several neoplasms. Shorter infusions are easier to administer, particularly in combination chemotherapy and combined-modality therapy, prompting our investigations of 1-hour paclitaxel infusions in more than 500 patients and approximately 2,000 treatment courses. The toxicity, activity, and pharmacology of 1- and 3-hour infusions of paclitaxel appear to be similar. Results of phase II trials document that 1-hour paclitaxel infusions can be administered safely, and notable activity has been seen against several neoplasms, including cancers of the lung, breast, and urothelium, as well as advanced squamous carcinomas and tumors of unknown origin. This report also describes some limited pharmacologic data of 1-hour paclitaxel compared with longer infusions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Rapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh.
Hosp Pharm
September 2024
Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Article Synopsis
- Antitumoral drugs (ADs) can trigger hypersensitivity reactions (DHRs), and rapid drug desensitization (RDD) protocols are employed to safely administer these treatments at effective doses.
- The "DESARCh" retrospective study assessed the RDD protocols carried out at an Italian hospital over 11 years, including a detailed 5-step infusion method to reduce DHR incidence for patients with various cancers.
- Out of 66 RDD protocols for 25 female patients, the overall success rate was 81.82%, although carboplatin had a significantly lower success rate compared to other ADs, highlighting the need for further research in this area.
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
Eur J Cancer
May 2024
Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address:
Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective studies, higher systemic exposure is associated with greater toxicity and efficacy of paclitaxel treatment across several disease types and dosing regimens.
View Article and Find Full Text PDFPre-clinical investigation of liquid sirolimus for local drug delivery.
Front Cardiovasc Med
September 2023
Department of Engineering, Wake Forest University, Winston-Salem, NC, United States.
Article Synopsis
- Sirolimus is being researched as a potential alternative to paclitaxel for treating peripheral artery disease (PAD), focusing on its delivery in liquid form rather than its traditional use in stent coatings.
- The pilot study assessed the feasibility of delivering liquid sirolimus using four drug delivery devices in a porcine artery model, measuring drug penetration and retention with advanced imaging and chromatography techniques.
- Results showed that the Occlusion Perfusion Catheter (OPC) provided the deepest drug penetration and successfully delivered liquid sirolimus at both 1 and 24 hours, indicating promising potential for this approach in PAD treatment.
Drink Tap: A Multisector Program to Promote Water Access and Intake in San Francisco Parks.
Prev Chronic Dis
August 2023
Division of General Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Article Synopsis
- Taxes on sugar-sweetened beverages (SSBs) can help lower their consumption, and combining these taxes with improved access to safe drinking water may further enhance this effect.
- A study in San Francisco assessed the impact of the Drink Tap program, which increased water access in parks, alongside SSB taxes, finding significant increases in water consumption.
- The results suggest that pairing water access and promotion with SSB taxes is more effective in increasing water intake than taxes alone, although there were no significant reductions in the consumption of bottled water, juices, or SSBs.
Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study.
Cancer Manag Res
September 2022
Department of Medical Oncology 4, National Cancer Hospital of Vietnam, Hanoi, Vietnam.
Objective: To evaluate the outcome and safety of the paclitaxel, carboplatin, and capecitabine (TCX) regimen in patients with advanced gastric cancer.
Methods: Advanced gastric cancer patients received the TCX regimen for up to six cycles, which were 3 weeks apart. Paclitaxel (175 mg/m2) was given over a 3-hour infusion, followed by carboplatin in a 1-hour infusion on day 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!